THTX(Delisted)
Theratechnologies·NASDAQ
--
--(--)
THTX Profile
Theratechnologies Inc.
A biopharmaceutical company that focused on the innovative therapies for Human Immunodeficiency Virus
2015 Peel Street, 11th Floor, Montreal, Québec, Canada H3A 1T8
--
Theratechnologies Inc. was established on October 19, 1993 under the Companies Act (Quebec) IA Division or CAQ. The company is a biopharmaceutical company focused on the development and commercialization of innovative therapies to meet unmet medical needs. The company currently has two approved products: EGRIFTA SV and Trogarzo in the US. EGRIFTA SV (tisamorelin for injection) is a new formulation of EGRIFTA, originally approved by the FDA in November 2010 and marketed in the United States in January 2011. EGRIFTA SV was approved by the FDA in November 2018, launched in 2019, and has now replaced EGRIFTA in these countries. EGRIFTA SV can be stored at room temperature in a small vial with a higher concentration and therefore a smaller dose. EGRIFTA SV is currently the only therapy approved in the United States to reduce excess abdominal fat in HIV-infected lipodystrophy patients.
